3 Penny Stocks With Cash Rich Balance Sheets Worth A Closer Look

Inflation worries, rising bond yields and energy price shocks have pushed many investors back to basics, focusing on cash strength and resilience rather than hype. That is exactly where the Elite Penny Stocks screener comes in. Instead of chasing every low priced stock, it filters for companies with balance sheets that look better equipped to fund their plans and pursue growth targets. For investors hunting for the next potential multi bagger while central banks keep a close eye on inflation and wages, this curated list offers a focused starting point. Below, you will see 3 of the best stocks from this screener.

Cronos Group (TSX:CRON)

Overview: Cronos Group is a cannabinoid company that cultivates, produces, distributes, and markets cannabis products, including dried flower, pre-rolls, oils, vaporizers, edibles, and tinctures, across Canada, Israel, and select international markets under brands such as Spinach, Lord Jones, Lit, and Peace Naturals.

Operations: Cronos Group generates about US$159.5m from cultivating, manufacturing, and marketing cannabis and cannabis derived products, with revenue concentrated in Canada (US$95.6m), followed by Israel (US$46.7m) and other countries (US$17.3m).

Market Cap: CA$1.48b

Cronos Group stands out in this penny stock-focused list because it combines a global cannabis footprint with brand strength in higher margin formats such as vapes, edibles, and pre-rolls. It also holds a large cash position and no debt, which provides flexibility to fund product launches and international expansion. Recent profitability at the quarterly level, active share buybacks, and analyst expectations for earnings to turn positive in the next few years are factors that point to a company working to move past its cash burn phase. Investors still need to weigh risks around regulation, reliance on cultivation expansion projects, and a relatively high P/S multiple versus peers.

Cronos Group’s cash rich, debt free position could be masking a very different risk and reward profile than its P/S multiple suggests, so it is worth reviewing the DCF valuation analysis for Cronos Group to see what the market might be missing.

CEMATRIX (TSX:CEMX)

Overview: CEMATRIX is a Calgary based construction materials company that produces and installs cellular concrete across North America, supplying lightweight, flowable concrete solutions for infrastructure, industrial, and commercial projects.

Operations: CEMATRIX generates about CA$45.7m from supplying and placing cellular concrete, with revenue split between Canada (CA$11.7m) and the United States (CA$34.1m).

Market Cap: CA$76.4m

CEMATRIX appears in this penny stock screener because it sits at the crossroads of infrastructure spending and demand for more sustainable building materials, supported by a record CA$76.4m backlog and ongoing contract wins in Canada and the US. The company operates with a scalable production base, and share buybacks can gradually increase the ownership stake of remaining shareholders over time. At the same time, lumpy project timing, intense competition for large jobs, and exposure to North American construction cycles contribute to the overall risk profile. For investors comfortable with that trade off, the mix of recent profitability, backlog strength, and active capital returns makes CEMATRIX a company that may warrant closer research.

CEMATRIX’s record CA$76.4m backlog and recent profitability could be masking a much bigger story about future contracts and margins, so walk through the analysis report for CEMATRIX to see what the headline numbers might be missing.

Cannara Biotech (TSX:LOVE)

Overview: Cannara Biotech is a Canadian cannabis producer that grows, processes, and sells branded cannabis and CBD products under the TRIBAL, nugz, and ORCHID CBD labels, while also generating income from real estate operations.

Operations: Cannara Biotech generates about CA$112.8m from cannabis operations and CA$3.9m from real estate, with total revenue of roughly CA$117.3m coming from Canada.

Market Cap: CA$186.7m

Cannara Biotech combines indoor cultivation scale, premium brands, and real estate income with a track record of more than 20 consecutive quarters of positive adjusted EBITDA and recent Q3 2026 revenue of CA$31.8m. Earnings and revenue are forecast to grow faster than the Canadian market, yet profit margins have slipped from 15.2% to 9.3% and Return on Equity sits at 8.6%. Funding risk and pressure on profitability are important to watch. Recent agreements with Curaleaf International and Blue River’s Ampersand, along with EU GMP ambitions, show how the company is targeting higher value export and product opportunities. Investors who focus only on the headline growth story may overlook how capacity additions, margin trends, and higher funding risk could influence results.

Cannara Biotech’s mix of growth, real estate income, and thinner margins suggests the headline story may not match the full risk and reward profile, so walk through the analyst forecasts for Cannara Biotech and see what could change the script.

The three stocks covered here are just the starting point, and the full Elite Penny Stocks screener highlights 8 more companies with equally compelling cash positions and growth narratives waiting to be analyzed. Use Simply Wall St to identify, filter, and analyze the exact catalysts and storylines that matter to you so you can focus on the highest conviction penny stock ideas without losing time in the noise.

Take Control of Your Investment Journey

If Cannara Biotech or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About Seeking Stronger Alternatives?

Fresh ideas can move before the headlines catch up, and early momentum often goes to investors who spot quality while it matters and while it is still under the radar, and who get in early.

• Spot companies quietly building momentum with resilient earnings and solid balance sheets by checking out the 11 resilient stocks with low risk scores before the crowd catches on.
• Catch potential breakout infrastructure suppliers and grid enablers using the curated 35 power grid technology and infrastructure stocks while these stories are still flying under most radars.
• Target companies involved in the AI build out with strong picks from the 54 AI infrastructure stocks before valuations start changing or momentum shifts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com